MIMEDX GROUP, INC. (MDXG) MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Biotechnology
MiMedx Group, Inc. NASDAQ:MDXG Healthcare · Biotechnology
AH Close $3.91 +0.00% vs close
AH Close $3.91 +0.00% vs close
All Press Release SEC Filings News
News
Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)
defenseworld.net • 8d ago SEC Filing ⚠ 1
MDXG: 8-K · acquisition merger
MiMedx Group and Sanara MedTech each received a Second Request from the FTC on October 15, 2026, in connection with the FTC's antitrust review of MiMedx's pending acquisition of Sanara.
The Second Request extends the Hart-Scott-Rodino waiting period until 30 days after the parties substantially comply, unless extended voluntarily or terminated earlier by the FTC.
MiMedx says it continues to work constructively with the FTC and that completion of the merger remains subject to expiration or termination of the HSR waiting period plus other closing conditions, so the deal timeline is now extended but not derailed.
SEC 8-K • 9d ago Press Release
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
MiMedx Group announced it will report third quarter 2026 operating and financial results after market close on Wednesday, October 28, 2026.
Senior management will host a webcast and conference call at 4:30 p.m. Eastern Time the same day, with a replay available for approximately 30 days on the company's website.
This is a routine scheduling notice with no financial results or guidance included.
• 11d ago AI analysis › News
MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Rating of “Moderate Buy” from Analysts
defenseworld.net • 19d ago News
Compugen (NASDAQ:CGEN) versus MiMedx Group (NASDAQ:MDXG) Head-To-Head Comparison
defenseworld.net • 1mo ago News
Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Review
defenseworld.net • 1mo ago Press Release ⚠ 1
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
MiMedx won a favorable ruling from the U.S. District Court for the Northern District of Georgia vacating FDA determinations that AXIOFILL is more than minimally manipulated and should be classified as a biological product.
The Court held FDA misinterpreted its minimal-manipulation regulation and called the agency's divergent classification of AXIOFILL versus similar products "arbitrary and capricious," remanding both matters to FDA.
The ruling preserves AXIOFILL's Section 361 HCT/P pathway, but FDA will reconsider the classification on remand, leaving some regulatory outcome uncertainty.
• 1mo ago AI analysis › Press Release
MIMEDX to Participate in Upcoming Investor Conferences
MiMedx Group announced that members of its senior management will participate in two upcoming investor conferences in New York.
The events are the Cantor Global Healthcare Conference on September 9, 2026, and the Lake Street BIG10 Best Ideas Growth Conference on September 10, 2026, both featuring 1:1 meetings with management.
This is a routine IR calendar notice with no new financial, clinical, or operational disclosures; interested investors can arrange meetings through their Cantor or Lake Street representatives.
• 1mo ago AI analysis › SEC Filing ⚠ 5
MDXG: 424B3 · acquisition merger
MiMedx Group has filed the definitive proxy statement/prospectus for its proposed acquisition of Sanara MedTech, under which each Sanara share will be converted into $33.00 in cash plus 0.4735 shares of MiMedx common stock, an implied value of $35.14 per Sanara share as of September 1, 2026.
MiMedx shareholders are expected to own approximately 97.1% of the combined company after closing, with Sanara holders receiving about 2.9%. The cash portion is backed by a $300.0 million first lien senior secured term loan commitment from funds managed by Hayfin Capital Management, and MiMedx expects to repay and terminate its existing credit facility at closing.
Sanara shareholders vote at a virtual special meeting on September 30, 2026, with holders of 39.0% of Sanara shares already committed under a voting agreement tied to Ronald T. Nixon. The HSR waiting period expires September 11, 2026, closing is expected in the fourth quarter of 2026, and termination fees of $9,660,336 (payable by Sanara) or $22,540,785 (payable by MiMedx) apply in specified scenarios.
SEC 424B3 • 1mo ago AI analysis › SEC Filing ● Major ⚠ 5
MDXG: S-4 · acquisition merger
MiMedx Group filed an S-4 registration statement covering the shares to be issued for its acquisition of Sanara MedTech under the merger agreement signed July 29, 2026. Each Sanara share will be converted into $33.00 in cash plus 0.4735 MiMedx shares, an implied value of $35.06 per SMTI share based on July 28, 2026 prices.
The cash portion will be funded partly by a $300.0 million first lien senior secured term loan committed by funds managed by Hayfin Capital Management, with MiMedx expecting to repay its existing credit facility. Termination fees are set at $9,660,336 payable by Sanara and $22,540,785 payable by MiMedx if it fails to close.
Closing requires Sanara shareholder approval, expiration of the HSR waiting period (September 11, 2026), and S-4 effectiveness, with completion expected in Q4 2026. Sanara will be delisted from Nasdaq and become a wholly-owned MiMedx subsidiary, with no changes anticipated to MiMedx's board or executive team.
SEC S-4 • 2mo ago SEC Filing ● Critical ⚠ 4
MDXG: 8-K/A · acquisition merger
MiMedx Group filed this 8-K/A to correct an error in its July 29, 2026 merger agreement disclosure with Sanara MedTech: the correct termination fee payable by Sanara is $9,660,336.00 and the correct fee payable by MiMedx is $22,540,785.00 — the two amounts were transposed in the original filing. No other disclosures were changed.
Under the merger agreement, MiMedx will acquire Sanara MedTech via a reverse triangular merger, with Sanara shareholders receiving $33.00 in cash plus 0.4735 MiMedx shares (valued at $2.00) for each Sanara share. Both boards unanimously approved the deal, and Sanara stockholders holding approximately 38.9% of voting power have signed a voting agreement in support.
MiMedx secured a $300.0 million first lien senior secured term loan commitment from funds managed by Hayfin Capital Management to help fund the transaction; MiMedx's existing credit agreement will be terminated and any outstanding amounts repaid in full when definitive financing documents are executed.
The deal must close by the July 29, 2027 end date (extendable to January 29, 2028 for antitrust approvals) and remains conditioned on S-4 effectiveness, HSR clearance, and Sanara stockholder approval. The corrected fee structure shows the acquirer, MiMedx, would owe Sanara the larger break fee if it fails to complete the merger.
SEC 8-K/A • 2mo ago News
MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript
seekingalpha.com • 2mo ago News
MiMedx Group Q2 Earnings Call Highlights
marketbeat.com • 2mo ago SEC Filing ● Major ⚠ 3
MDXG: 425 · acquisition merger
MIMEDX and Sanara MedTech announced a definitive agreement to combine, creating what is expected to be one of the largest regenerative medicine companies across numerous surgical subspecialties. The transaction is anticipated to close by the end of 2026, subject to Sanara shareholder approval and customary closing conditions including regulatory approvals.
Until closing, both companies will continue to operate as separate, independent entities. MIMEDX stated that this acquisition accelerates its surgical market presence and combines two focused organizations with strong momentum in the surgical space.
Integration planning is underway, with a steering committee comprising members of both management teams working alongside an advisory firm. No final decisions have been made regarding workforce reductions or organizational structure changes at this time.
SEC 425 • 2mo ago Press Release ● Major ⚠ 5
MIMEDX Announces Second Quarter 2026 Operating & Financial Results
MIMEDX reported Q2 2026 net sales of $64 million, a 35% decrease from the prior year, and posted a net loss of $15 million compared to net income of $10 million in Q2 2025. Despite the top-line decline, management reiterated its full-year 2026 net sales guidance of $260-290 million and noted that cost reduction actions are putting the company on a path back to profitability in the second half.
Operationally, the Surgical franchise delivered 15% year-over-year revenue growth, offset by a 61% decline in Wound sales driven by Medicare reimbursement changes. The company highlighted a 22% sequential increase in overall Wound volume as evidence of recovery within the new reimbursement landscape.
Simultaneously, MIMEDX announced a definitive agreement to acquire Sanara MedTech for approximately $350 million in an enterprise value transaction. The deal, valued at $35 per Sanara share, will be funded through cash on hand and a new $300 million term loan from Hayfin Capital Management.
• 2mo ago AI analysis › Press Release ● Critical
MIMEDX to Acquire Sanara MedTech
MIMEDX announced a definitive agreement to acquire Sanara MedTech for approximately $350 million in enterprise value, or $35.00 per share, in a cash and stock transaction.
The transaction is expected to be immediately accretive to revenue growth and adjusted EBITDA margins, targeting over $400 million in combined 2027 revenue with more than $20 million in anticipated run-rate cost synergies.
MIMEDX plans to finance the cash portion using existing cash and a new $300 million term loan from Hayfin Capital Management, with the deal expected to close by the end of 2026.
• 2mo ago AI analysis › Press Release
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29
MiMedx announced it will report its second quarter 2026 operating and financial results after the market closes on Wednesday, July 29, 2026.
Senior management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to review the performance for the quarter ended June 30, 2026.
A replay of the call will be accessible on the company's website for approximately 30 days following the event.
• 3mo ago AI analysis › SEC Filing
MDXG: 8-K · proxy statement
MiMedx Group held its 2026 Annual Meeting of Shareholders on June 10, 2026, where approximately 84.2% of outstanding shares were represented in person or by proxy. Shareholders re-elected seven directors to the Board, including Joseph H. Capper, James L. Bierman, and William A. Hawkins, III, all of whom received significant support. Additionally, the meeting resulted in the approval of an advisory resolution regarding executive compensation and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Concurrent with the annual meeting, the Board of Directors approved an amendment to the Company's Amended & Restated Bylaws. This amendment increases the number of boards of directors of public companies that the Company's chief executive officer may sit on to three.
SEC 8-K • 4mo ago Press Release ⚠ 3
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
Conexeu Sciences reports transferring standardized formulation methods to its CDMO and advancing manufacturing scale-up activities for its lead wound-care device candidate.
The company is preparing a 510(k) premarket notification targeted for the first quarter of 2027, supported by prior FDA pre-submission feedback through the Q-Submission process.
Development of the CXU™ platform includes a preclinical breast matrix program in collaboration with Wake Forest Institute for Regenerative Medicine, targeting broader applications beyond wound care.
• 4mo ago AI analysis › Press Release ⚠ 3
A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
Conexeu Sciences is advancing its lead CXU wound-care program into manufacturing scale-up and regulatory preparation, targeting a 510(k) submission in Q1 2027.
The company has transferred standardized formulation methods to a CDMO and is producing representative materials for analytical, biocompatibility, and sterilization testing.
This operational progress marks a transition from research-stage development to regulatory-execution activities, supported by prior FDA pre-submission feedback.
• 4mo ago AI analysis › Press Release
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MiMedx Group announced that senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference.
The event is scheduled for Thursday, May 28, 2026, in Minneapolis, MN.
Investors interested in meeting with management are directed to contact their Craig-Hallum representative.
• 5mo ago AI analysis › Press Release
MIMEDX Announces Launch of G4Derm® Plus
globenewswire.com • 5mo ago Press Release ● Major ⚠ 4
MIMEDX Announces First Quarter 2026 Operating & Financial Results
MIMEDX reported Q1 net sales of $59 million, a 33% decrease from the prior year, driven by new Medicare reimbursement policies that caused significant market disruption and confusion.
Due to these headwinds, the company lowered full-year 2026 sales guidance to a range of $260 to $290 million and expects Adjusted EBITDA to be approximately breakeven.
Despite the Wound segment declining 60%, Surgical sales grew 13% year-over-year, and the company is implementing cost adjustments expected to generate $40 million in annualized savings.
• 5mo ago AI analysis › Press Release
MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
globenewswire.com • 6mo ago Press Release ● Major
MIMEDX Announces Restructuring and Cost Reduction Initiative
globenewswire.com • 6mo ago 
